Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Fallopian Tube Neoplasms"" wg kryterium: Temat


Tytuł :
Challenges and management options of tubo-ovarian cancer in the midst of SARS-CoV-2 pandemic.
Autorzy :
Tranoulis A; Department of Gynaecological Oncology, Maidstone and Turnbridge Wells NHS Trust, UK. Electronic address: .
Georgiou D; Department of Gynaecology, Chelsea and Westminster NHS Trust, Imperial College, London, UK.
Pokaż więcej
Źródło :
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2020 Nov; Vol. 46 (11), pp. 2160-2161. Date of Electronic Publication: 2020 Jun 30.
Typ publikacji :
Letter
MeSH Terms :
Pandemics*/prevention & control
Coronavirus Infections/*epidemiology
Fallopian Tube Neoplasms/*surgery
Ovarian Neoplasms/*surgery
Pneumonia, Viral/*epidemiology
Betacoronavirus ; Coronavirus Infections/prevention & control ; Fallopian Tube Neoplasms/diagnosis ; Fallopian Tube Neoplasms/drug therapy ; Female ; Humans ; Ovarian Neoplasms/diagnosis ; Ovarian Neoplasms/drug therapy ; Patient Selection ; Pneumonia, Viral/prevention & control ; Practice Guidelines as Topic ; United Kingdom/epidemiology
SCR Disease Name :
COVID-19
Opinia redakcyjna
Tytuł :
Incidental occurrence of high grade serous tubal adenocarcinoma after prophylactic adnexectomy in benign gynecological surgery.
Autorzy :
Kozolková D
Spodniaková B
Hajduková M
Hollý I
Záhumenský J
Pokaż więcej
Transliterated Title :
Náhodný výskyt high grade serózneho adenokarcinómu tuby v rámci profylaktickej adnexektómie pri benígnej gynekologickej operácii.
Źródło :
Ceska gynekologie [Ceska Gynekol] 2020 Winter; Vol. 85 (2), pp. 111-115.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Prophylactic Surgical Procedures*
Adenocarcinoma/*surgery
Adnexal Diseases/*surgery
Fallopian Tube Neoplasms/*surgery
Gynecologic Surgical Procedures/*methods
Adenocarcinoma/pathology ; Adnexal Diseases/pathology ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; Hysterectomy, Vaginal ; Incidental Findings ; Ovarian Neoplasms/pathology ; Ovarian Neoplasms/surgery ; Salpingectomy ; Treatment Outcome
Czasopismo naukowe
Tytuł :
[Efficacy of Olaparib Treatment for Platinum-Sensitive Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancers].
Autorzy :
Takei T; Dept. of Obstetrics and Gynecology, Kansai Rosai Hospital.
Takaki E
Tsuji S
Onoue M
Yamashita M
Yoshioka E
Goto M
Tashima L
Ito K
Hori K
Pokaż więcej
Źródło :
Gan to kagaku ryoho. Cancer & chemotherapy [Gan To Kagaku Ryoho] 2020 Oct; Vol. 47 (10), pp. 1457-1460.
Typ publikacji :
Journal Article
MeSH Terms :
Fallopian Tube Neoplasms*/drug therapy
Ovarian Neoplasms*/drug therapy
Fallopian Tubes ; Female ; Humans ; Neoplasm Recurrence, Local ; Phthalazines ; Piperazines ; Platinum
Czasopismo naukowe
Tytuł :
Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study.
Autorzy :
Van Calster B; Department of Development and Regeneration, KU Leuven, Herestraat 49 Box 805, 3000 Leuven, Belgium.; Department of Biomedical Data Sciences, Leiden University Medical Centre, Leiden, Netherlands.; EPI-Centre, KU Leuven, Leuven, Belgium.
Valentin L; Department of Obstetrics and Gynaecology, Skåne University Hospital, Malmö, Sweden.; Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Froyman W; Department of Development and Regeneration, KU Leuven, Herestraat 49 Box 805, 3000 Leuven, Belgium.; Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.
Landolfo C; Department of Development and Regeneration, KU Leuven, Herestraat 49 Box 805, 3000 Leuven, Belgium.; Queen Charlotte's and Chelsea Hospital, Imperial College, London, UK.
Ceusters J; Laboratory of Tumour Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, Belgium.
Testa AC; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario Agostino Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.; Department of Life Science and Public Health, Universita' Cattolica del Sacro Cuore, Rome, Italy.
Wynants L; Department of Development and Regeneration, KU Leuven, Herestraat 49 Box 805, 3000 Leuven, Belgium.; Department of Epidemiology, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, Netherlands.
Sladkevicius P; Department of Obstetrics and Gynaecology, Skåne University Hospital, Malmö, Sweden.; Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Van Holsbeke C; Department of Obstetrics and Gynaecology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Domali E; First Department of Obstetrics and Gynaecology, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Fruscio R; Clinic of Obstetrics and Gynaecology, University of Milan-Bicocca, San Gerardo Hospital, Monza, Italy.
Epstein E; Department of Clinical Science and Education, Karolinska Institutet, Stockholm, Sweden.; Department of Obstetrics and Gynaecology, Södersjukhuset, Stockholm, Sweden.
Franchi D; Preventive Gynaecology Unit, Division of Gynaecology, European Institute of Oncology IRCCS, Milan, Italy.
Kudla MJ; Department of Perinatology and Oncological Gynaecology, School of Health Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
Chiappa V; Department of Gynaecologic Oncology, National Cancer Institute of Milan, Milan, Italy.
Alcazar JL; Department of Obstetrics and Gynaecology, Clinica Universidad de Navarra, School of Medicine, Pamplona, Spain.
Leone FPG; Department of Obstetrics and Gynaecology, Biomedical and Clinical Sciences Institute L. Sacco, University of Milan, Milan, Italy.
Buonomo F; Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.
Coccia ME; Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy.
Guerriero S; Department of Obstetrics and Gynaecology, University of Cagliari, Policlinico Universitario Duilio Casula, Monserrato, Cagliari, Italy.
Deo N; Department of Obstetrics and Gynaecology, Whipps Cross Hospital, London, UK.
Jokubkiene L; Department of Obstetrics and Gynaecology, Skåne University Hospital, Malmö, Sweden.; Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Savelli L; Department of Obstetrics and Gynaecology, University of Bologna, Bologna, Italy.
Fischerová D; Gynaecological Oncology Centre, Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic.
Czekierdowski A; First Department of Gynaecological Oncology and Gynaecology, Medical University of Lublin, Lublin, Poland.
Kaijser J; Department of Obstetrics and Gynaecology, Ikazia Hospital, Rotterdam, Netherlands.
Coosemans A; Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.; Laboratory of Tumour Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, Belgium.; Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Scambia G; Department of Woman, Child and Public Health, Fondazione Policlinico Universitario Agostino Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy.; Department of Life Science and Public Health, Universita' Cattolica del Sacro Cuore, Rome, Italy.
Vergote I; Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.; Laboratory of Tumour Immunology and Immunotherapy, Department of Oncology, KU Leuven, Leuven, Belgium.; Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium.
Bourne T; Department of Development and Regeneration, KU Leuven, Herestraat 49 Box 805, 3000 Leuven, Belgium.; Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.; Queen Charlotte's and Chelsea Hospital, Imperial College, London, UK.
Timmerman D; Department of Development and Regeneration, KU Leuven, Herestraat 49 Box 805, 3000 Leuven, Belgium .; Department of Obstetrics and Gynaecology, University Hospitals Leuven, Leuven, Belgium.
Pokaż więcej
Źródło :
BMJ (Clinical research ed.) [BMJ] 2020 Jul 30; Vol. 370, pp. m2614. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji :
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Study
MeSH Terms :
Logistic Models*
Fallopian Tube Neoplasms/*diagnosis
Fallopian Tube Neoplasms/*pathology
Ovarian Neoplasms/*diagnosis
Ovarian Neoplasms/*pathology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; CA-125 Antigen/blood ; Calibration ; Conservative Treatment ; Fallopian Tube Neoplasms/therapy ; Female ; Humans ; Membrane Proteins/blood ; Middle Aged ; Ovarian Neoplasms/therapy ; Ovariectomy ; Prospective Studies ; Risk Assessment/methods ; Ultrasonography ; Young Adult
Czasopismo naukowe
Tytuł :
Reduced PAX2 expression in murine fallopian tube cells enhances estrogen receptor signaling.
Autorzy :
Colina JA; Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA.
Varughese P; Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA.
Karthikeyan S; Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA.
Salvi A; Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA.
Modi DA; Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA.
Burdette JE; Pharmaceutical Sciences, Center for Biomolecular Science, University of Illinois at Chicago, Chicago, IL, USA.
Pokaż więcej
Źródło :
Carcinogenesis [Carcinogenesis] 2020 Jul 10; Vol. 41 (5), pp. 646-655.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Epithelium/*pathology
Estrogens/*metabolism
Fallopian Tube Neoplasms/*pathology
Fallopian Tubes/*pathology
PAX2 Transcription Factor/*antagonists & inhibitors
Receptors, Estrogen/*metabolism
Animals ; Antineoplastic Agents/pharmacology ; Apoptosis ; Biomarkers, Tumor/genetics ; Biomarkers, Tumor/metabolism ; Cell Cycle ; Cell Movement ; Cell Proliferation ; Disease Models, Animal ; Epithelium/drug effects ; Epithelium/metabolism ; Fallopian Tube Neoplasms/drug therapy ; Fallopian Tube Neoplasms/genetics ; Fallopian Tube Neoplasms/metabolism ; Fallopian Tubes/drug effects ; Fallopian Tubes/metabolism ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; PAX2 Transcription Factor/genetics ; PAX2 Transcription Factor/metabolism ; Receptors, Estrogen/genetics ; Signal Transduction ; Transcriptome ; Tumor Cells, Cultured
Czasopismo naukowe
Tytuł :
Suppressive effect upon carboplatin hypersensitivity reaction via pegylated liposomal doxorubicin combination therapy.
Autorzy :
Shimada K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Nagao S; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan. .
Suzuki K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Shibutani T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Yamamoto K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Jimi T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Yano H; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Kitai M; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Shiozaki T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Yamaguchi S; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-city, Hyogo, 673-8558, Japan.
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2020 Sep; Vol. 25 (9), pp. 1718-1725. Date of Electronic Publication: 2020 May 23.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carboplatin/*adverse effects
Fallopian Tube Neoplasms/*drug therapy
Ovarian Neoplasms/*drug therapy
Peritoneal Neoplasms/*drug therapy
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/administration & dosage ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Fallopian Tube Neoplasms/mortality ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/mortality ; Peritoneal Neoplasms/mortality ; Polyethylene Glycols/administration & dosage ; Young Adult
Czasopismo naukowe
Tytuł :
Primary transitional cell carcinoma of the fallopian tube: A case report and literature review.
Autorzy :
Lee DH; Department of Obstetrics and Gynecology, Jeonbuk National University Hospital-Jeonbuk National University Medical School.; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital.
Cho DH; Department of Obstetrics and Gynecology, Jeonbuk National University Hospital-Jeonbuk National University Medical School.; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital.
Kim KM; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital.; Department of Pathology.
Yim CY; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital.; Division of Hematology and oncology, Department of Internal Medicine, Jeonbuk National University Hospital-Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Lee NR; Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital.; Division of Hematology and oncology, Department of Internal Medicine, Jeonbuk National University Hospital-Jeonbuk National University Medical School, Jeonju, Republic of Korea.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 May 29; Vol. 99 (22), pp. e20499.
Typ publikacji :
Case Reports; Journal Article; Review
MeSH Terms :
Carcinoma, Transitional Cell/*diagnostic imaging
Carcinoma, Transitional Cell/*surgery
Fallopian Tube Neoplasms/*diagnostic imaging
Fallopian Tube Neoplasms/*surgery
Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carcinoma, Transitional Cell/pathology ; Cisplatin/therapeutic use ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/therapeutic use ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; Hysterectomy ; Magnetic Resonance Imaging ; Neoplasm Recurrence, Local/drug therapy ; Palliative Care ; Salpingo-oophorectomy
Czasopismo naukowe
Tytuł :
Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience.
Autorzy :
Chang CH; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Kuo HL; Department of Nursing, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Chen TC; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Weng CS; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Lim L; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Huang WC; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Chang CL; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Su TH; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Hsinchu Branch, Hsinchu 30071, Taiwan.
Wang KG; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Wang KL; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taitung Branch, Taitung 95054, Taiwan.; Department of General Education, MacKay Junior College of Medicine, Nursing and Management, New Taipei City 11260, Taiwan.
Yang YC; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.
Chen JR; Department of Obstetric & Gynecology, MacKay Memorial Hospital, Taipei 10449, Taiwan.; Department of General Education, MacKay Junior College of Medicine, Nursing and Management, New Taipei City 11260, Taiwan.
Pokaż więcej
Źródło :
International journal of environmental research and public health [Int J Environ Res Public Health] 2020 May 18; Vol. 17 (10). Date of Electronic Publication: 2020 May 18.
Typ publikacji :
Journal Article
MeSH Terms :
Chemotherapy, Adjuvant*
Fallopian Tube Neoplasms*/drug therapy
Fallopian Tube Neoplasms*/surgery
Ovarian Neoplasms*/drug therapy
Ovarian Neoplasms*/surgery
Peritoneal Neoplasms*/drug therapy
Peritoneal Neoplasms*/surgery
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Middle Aged ; Neoplasm Recurrence, Local ; Neoplasm Staging ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
Autorzy :
Rush SK; Department of Obstetrics & Gynecology, University of Washington Medical Center, United States of America.
Swisher EM; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Washington Medical Center, United States of America.
Garcia RL; Department of Pathology, University of Washington Medical Center, United States of America.
Pennington KP; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Washington Medical Center, United States of America.
Agnew KJ; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Washington Medical Center, United States of America.
Kilgore MR; Department of Pathology, University of Washington Medical Center, United States of America.
Norquist BM; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Washington Medical Center, United States of America. Electronic address: .
Pokaż więcej
Źródło :
Gynecologic oncology [Gynecol Oncol] 2020 May; Vol. 157 (2), pp. 514-520. Date of Electronic Publication: 2020 Mar 19.
Typ publikacji :
Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Fallopian Tube Neoplasms/*prevention & control
Fallopian Tubes/*surgery
Ovarian Neoplasms/*prevention & control
Ovary/*surgery
Adult ; Aged ; BRCA2 Protein/genetics ; Cohort Studies ; Fallopian Tube Neoplasms/genetics ; Fallopian Tube Neoplasms/pathology ; Fanconi Anemia Complementation Group N Protein/genetics ; Female ; Genetic Predisposition to Disease ; Humans ; Middle Aged ; Mutation ; Neoplasms, Unknown Primary/diagnosis ; Neoplasms, Unknown Primary/pathology ; Ovarian Neoplasms/genetics ; Ovarian Neoplasms/pathology ; Pedigree ; Prospective Studies ; Salpingo-oophorectomy ; Ubiquitin-Protein Ligases/genetics
Czasopismo naukowe
Tytuł :
The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
Autorzy :
Rudaitis V; Vilnius University Hospital Santaros Clinics, Department of Gynecology, Santariskiu st. 2, Vilnius, Lithuania; Vilnius University, Faculty of Medicine, Clinic of Obstetrics and Gynaecology, Ciurlionio st. 21, Vilnius, Lithuania; Vilnius University Hospital Santaros Clinics, Centre of Pathology, P.Baublio st. 5, Vilnius, Lithuania.
Mikliusas V; Vilnius University Hospital Santaros Clinics, Department of Gynecology, Santariskiu st. 2, Vilnius, Lithuania; Spital STS AG, Frauenklinik, Krankenhausstrasse 12, Thun, Switzerland.
Januska G; Vilnius University Hospital Santaros Clinics, Department of Gynecology, Santariskiu st. 2, Vilnius, Lithuania.
Jukna P; Vilnius University, Faculty of Medicine, Clinic of Obstetrics and Gynaecology, Ciurlionio st. 21, Vilnius, Lithuania.
Mickys U; Vilnius University Hospital Santaros Clinics, Centre of Pathology, P.Baublio st. 5, Vilnius, Lithuania.
Janavicius R; Vilnius University Hospital Santaros Clinics, Hematology, Oncology and Transfusion Medicine Center, Hereditary Cancer Center, Santariskiu st. 2, Vilnius, Lithuania; State Research Institute Innovative Medicine Center, Santariskiu st. 5, Vilnius, Lithuania. Electronic address: .
Pokaż więcej
Źródło :
European journal of obstetrics, gynecology, and reproductive biology [Eur J Obstet Gynecol Reprod Biol] 2020 Apr; Vol. 247, pp. 26-31. Date of Electronic Publication: 2020 Jan 30.
Typ publikacji :
Journal Article
MeSH Terms :
Fallopian Tube Neoplasms/*prevention & control
Ovarian Neoplasms/*prevention & control
Ovariectomy/*statistics & numerical data
Adult ; Aged ; BRCA1 Protein ; BRCA2 Protein ; Fallopian Tube Neoplasms/epidemiology ; Fallopian Tube Neoplasms/genetics ; Female ; Germ-Line Mutation ; Humans ; Incidence ; Middle Aged ; Ovarian Neoplasms/epidemiology ; Ovarian Neoplasms/genetics ; Prospective Studies
Czasopismo naukowe
Tytuł :
Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms Associated With Germline and Somatic DICER1 Mutations.
Autorzy :
McCluggage WG; Department of Pathology, Belfast Health and Social Care Trust, Belfast, Northern Ireland.
Apellaniz-Ruiz M; Department of Human Genetics, McGill University.; Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montréal, QC, Canada.
Chong AL; Department of Human Genetics, McGill University.; Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montréal, QC, Canada.
Hanley KZ; Department of Pathology, and Laboratory Medicine, Emory University Hospital.
Velázquez Vega JE; Department of Pathology and Laboratory Medicine, Children's Healthcare of Atlanta and Emory University, Atlanta, GA.
McVeigh TP; Cancer Genetics Unit, Royal Marsden NHS Foundation Trust, London, United Kingdom.
Foulkes WD; Department of Human Genetics, McGill University.; Cancer Axis, Lady Davis Institute, Jewish General Hospital, Montréal, QC, Canada.
Pokaż więcej
Źródło :
The American journal of surgical pathology [Am J Surg Pathol] 2020 Jun; Vol. 44 (6), pp. 738-747.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
DEAD-box RNA Helicases/*genetics
Fallopian Tube Neoplasms/*genetics
Neoplastic Syndromes, Hereditary/*genetics
Ovarian Neoplasms/*genetics
Rhabdomyosarcoma, Embryonal/*genetics
Ribonuclease III/*genetics
Adolescent ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; Middle Aged ; Mutation ; Ovarian Neoplasms/pathology ; Rhabdomyosarcoma, Embryonal/pathology
Czasopismo naukowe
Tytuł :
Comparisons of Clinical Outcomes in Women with Advanced Ovarian Cancer Treated with Frontline Intraperitoneal versus Dose-Dense Platinum/Paclitaxel Chemotherapy without Bevacizumab.
Autorzy :
Ting WH; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.
Hsiao CH; Division of Medical Oncology and Hematology, Department of Internal Medicine, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.
Chen HH; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.
Wei MC; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.
Lin HH; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.; Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100225, Taiwan.
Hsiao SM; Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, New Taipei 220409, Taiwan.; Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei 100225, Taiwan.; Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan 320315, Taiwan.
Pokaż więcej
Źródło :
International journal of environmental research and public health [Int J Environ Res Public Health] 2020 May 20; Vol. 17 (10). Date of Electronic Publication: 2020 May 20.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols*/therapeutic use
Fallopian Tube Neoplasms*/drug therapy
Ovarian Neoplasms*/drug therapy
Bevacizumab/administration & dosage ; Carboplatin ; Disease-Free Survival ; Female ; Humans ; Infusions, Parenteral ; Middle Aged ; Paclitaxel/administration & dosage ; Platinum/administration & dosage
Czasopismo naukowe
Tytuł :
Anterior mediastinal metastasis of primary fallopian tube adenocarcinoma: a case report.
Autorzy :
Zhang B; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China.
Liu R; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China.; Department of Lung Cancer Surgery; Tianjin key laboratory of lung cancer metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Anshan Road No.154, Heping District, Tianjin, 300052, China.
Li T; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China.
Chen F; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China.
Huo H; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China.
Ren D; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China.; Department of Lung Cancer Surgery; Tianjin key laboratory of lung cancer metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Anshan Road No.154, Heping District, Tianjin, 300052, China.
Ren F; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China.; Department of Lung Cancer Surgery; Tianjin key laboratory of lung cancer metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Anshan Road No.154, Heping District, Tianjin, 300052, China.
Xu S; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China.; Department of Lung Cancer Surgery; Tianjin key laboratory of lung cancer metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Anshan Road No.154, Heping District, Tianjin, 300052, China.
Xu X; Colleges of Nursing, Tianjin Medical University, Qixiangtai Road No.22, Tianjin, 300070, China. .
Song Z; Department of Lung Cancer Surgery, Tianjin Medical University General Hospital, Anshan Road No 154, Heping District, Tianjin, 300052, China. .; Department of Lung Cancer Surgery; Tianjin key laboratory of lung cancer metastasis and tumor microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Anshan Road No.154, Heping District, Tianjin, 300052, China. .
Pokaż więcej
Źródło :
Journal of cardiothoracic surgery [J Cardiothorac Surg] 2020 May 11; Vol. 15 (1), pp. 77. Date of Electronic Publication: 2020 May 11.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Adenocarcinoma/*pathology
Fallopian Tube Neoplasms/*pathology
Mediastinal Neoplasms/*secondary
Mediastinum/*pathology
Neoplasm Recurrence, Local/*surgery
Adenocarcinoma/surgery ; Aged ; Fallopian Tube Neoplasms/surgery ; Fallopian Tubes ; Female ; Humans ; Incidence ; Mediastinal Neoplasms/surgery
Czasopismo naukowe
Tytuł :
Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
Autorzy :
Pfisterer J; Gynaecologic Oncology Center, Kiel, Germany. Electronic address: .
Shannon CM; Oncology Department, Mater Cancer Care Centre, Brisbane, QLD, Australia.
Baumann K; Gynaecology Department, Klinikum der Stadt Ludwigshafen am Rhein, Ludwigshafen, Germany.
Rau J; Coordinating Center for Clinical Trials, Philipps-University, Marburg, Germany.
Harter P; Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany.
Joly F; Gynaecology Department, Centre François Baclesse, Caen, France.
Sehouli J; Department of Gynaecology, and European Competence Center for Ovarian Cancer, Charité - Universitätsmedizin Berlin, Campus Virchow, Berlin, Germany.
Canzler U; Department of Gynaecology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Schmalfeldt B; Technical University of Munich-Klinikum Rechts der Isar, Germany; Department of Gynaecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Dean AP; Gynaecological Oncology Department, St John of God Hospital, Subiaco, WA, Australia.
Hein A; Gynaecology Department, Erlangen University Hospital, Erlangen, Germany.
Zeimet AG; Department of Obstetrics and Gynaecology, Innsbruck Medical University, Innsbruck, Austria.
Hanker LC; Gynaecology Department, University Hospital Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.
Petit T; Paul Strauss Cancer Center and Gynaecology Department, University of Strasbourg, Strasbourg, France.
Marmé F; Gynaecology Department, National Center for Tumor Disease, University of Heidelberg, Heidelberg, Germany; Department of Gynaecology and Obstetrics, University Hospital Mannheim, Mannheim, Germany.
El-Balat A; Department of Gynaecology and Obstetrics, University of Frankfurt/Main, Frankfurt, Germany.
Glasspool R; National Cancer Research Institute, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK.
de Gregorio N; Department of Obstetrics and Gynaecology, University of Ulm, Ulm, Germany.
Mahner S; Department of Gynaecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Obstetrics and Gynaecology, University Hospital, Ludwig-Maximilian-University, Munich, Germany.
Meniawy TM; Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia.
Park-Simon TW; Department of Gynaecology and Obstetrics, Medical University Hannover, Hannover, Germany.
Mouret-Reynier MA; Department of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.
Costan C; Department of Oncology, Hôpital Michallon, Grenoble, France.
Meier W; Department of Gynaecology and Obstetrics, Evangelisches Krankenhaus Düsseldorf, Germany; Department of Gynaecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf, Germany.
Reinthaller A; Department of Gynecology and Gynecologic Oncology, Comprehensive Cancer Centre, University Hospital for Gynaecology, Medical University Vienna, Vienna, Austria.
Goh JC; Royal Brisbane & Women's Hospital, Brisbane, QLD, Australia.
L'Haridon T; Centre Hospitalier Départemental les Oudairies, La Roche-Sur-Yon, France.
Baron Hay S; Women's Health, Royal North Shore Hospital, Sydney, NSW, Australia.
Kommoss S; Department of Women's Health, Tübingen University Hospital, Tübingen, Germany.
du Bois A; Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany.
Kurtz JE; Haematology-Oncology Department, Centre Hospitalier Régional et Universitaire de Strasbourg Hôpital Civil, Strasbourg, France.
Pokaż więcej
Corporate Authors :
AGO-OVAR 2.21/ENGOT-ov 18 Investigators
Źródło :
The Lancet. Oncology [Lancet Oncol] 2020 May; Vol. 21 (5), pp. 699-709. Date of Electronic Publication: 2020 Apr 16.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Bevacizumab/*administration & dosage
Fallopian Tube Neoplasms/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Ovarian Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Australia/epidemiology ; Austria/epidemiology ; Bevacizumab/adverse effects ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Doxorubicin/administration & dosage ; Doxorubicin/analogs & derivatives ; Fallopian Tube Neoplasms/pathology ; Female ; France/epidemiology ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Ovarian Neoplasms/pathology ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Platinum/administration & dosage ; Platinum/adverse effects ; Polyethylene Glycols/administration & dosage
Czasopismo naukowe
Tytuł :
Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial.
Autorzy :
Onda T; Department of Gynecology, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: .
Satoh T; Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
Ogawa G; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Saito T; Gynecology Service, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kasamatsu T; Department of Gynecologic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Nakanishi T; Department of Gynecologic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Mizutani T; JCOG Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
Takehara K; Department of Gynecologic Oncology, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
Okamoto A; Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Ushijima K; Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan.
Kobayashi H; Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Kawana K; Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, Tokyo, Japan.
Yokota H; Department of Gynecology, Saitama Cancer Center, Kita Adachi Gun, Japan.
Takano M; Department of Clinical Oncology, National Defense Medical College Hospital, Tokorozawa, Japan.
Kanao H; Department of Gynecological Oncology, Cancer Institute Hospital, Tokyo, Japan.
Watanabe Y; Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Yamamoto K; Department of Obstetrics and Gynecology, Faculty of Medicine, Kindai University, Sakai Hospital, Sakai, Japan.
Yaegashi N; Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Kamura T; Medical Care Education Research Foundation, Yanagawa Hospital, Yanagawa, Japan.
Yoshikawa H; Ibaraki Prefectural Central Hospital, Kasama, Japan.
Pokaż więcej
Corporate Authors :
Japan Clinical Oncology Group
Źródło :
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2020 May; Vol. 130, pp. 114-125. Date of Electronic Publication: 2020 Mar 13.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Ovarian Epithelial/*surgery
Cytoreduction Surgical Procedures/*methods
Fallopian Tube Neoplasms/*surgery
Neoadjuvant Therapy/*methods
Peritoneal Neoplasms/*surgery
Adult ; Aged ; Carcinoma, Ovarian Epithelial/mortality ; Fallopian Tube Neoplasms/mortality ; Female ; Humans ; Middle Aged ; Neoplasm Staging ; Peritoneal Neoplasms/mortality
Czasopismo naukowe
Tytuł :
Clinical relevance of circulating tumor cells in ovarian, fallopian tube and peritoneal cancer.
Autorzy :
Banys-Paluchowski M; Department of Gynecology and Obstetrics, Asklepios Klinik Barmbek, Rübenkamp 220, 22307, Hamburg, Germany.
Fehm T; Department of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.
Neubauer H; Department of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.
Paluchowski P; Department of Gynecology and Obstetrics, Regio Klinik Pinneberg, Fahltskamp 74, 25421, Pinneberg, Germany.
Krawczyk N; Department of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.
Meier-Stiegen F; Department of Obstetrics and Gynecology, Heinrich-Heine-University Düsseldorf, Moorenstr. 5, 40225, Düsseldorf, Germany.
Wallach C; Department of Gynecology and Obstetrics, Regio Klinik Pinneberg, Fahltskamp 74, 25421, Pinneberg, Germany.
Kaczerowsky A; Department of Gynecology and Obstetrics, Marienkrankenhaus Hamburg, Alfredstr. 9, 22087, Hamburg, Germany.
Gebauer G; Department of Gynecology and Obstetrics, Asklepios Klinik Barmbek, Rübenkamp 220, 22307, Hamburg, Germany. .
Pokaż więcej
Źródło :
Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2020 Apr; Vol. 301 (4), pp. 1027-1035. Date of Electronic Publication: 2020 Mar 06.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Biomarkers, Tumor/*blood
Fallopian Tube Neoplasms/*physiopathology
Neoplastic Cells, Circulating/*pathology
Ovarian Neoplasms/*physiopathology
Peritoneal Neoplasms/*physiopathology
Fallopian Tube Neoplasms/mortality ; Female ; Humans ; Ovarian Neoplasms/mortality ; Peritoneal Neoplasms/mortality ; Prognosis ; Prospective Studies ; Survival Analysis
Czasopismo naukowe
Tytuł :
Dose-dense paclitaxel and carboplatin vs. conventional paclitaxel and carboplatin as neoadjuvant chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: a retrospective study.
Autorzy :
Shibutani T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Nagao S; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan. .
Suzuki K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Kaneda M; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Yamamoto K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Jimi T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Yano H; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Kitai M; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Shiozaki T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Matsuoka K; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Sudo T; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Yamaguchi S; Department of Gynecologic Oncology, Hyogo Cancer Center, 13-70 Kitaoji-cho, Akashi-City, 673-8558, Hyogo, Japan.
Pokaż więcej
Źródło :
International journal of clinical oncology [Int J Clin Oncol] 2020 Mar; Vol. 25 (3), pp. 502-507. Date of Electronic Publication: 2019 Nov 01.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Carcinoma, Ovarian Epithelial/*drug therapy
Fallopian Tube Neoplasms/*drug therapy
Peritoneal Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Carboplatin/administration & dosage ; Carcinoma, Ovarian Epithelial/mortality ; Carcinoma, Ovarian Epithelial/surgery ; Cytoreduction Surgical Procedures ; Fallopian Tube Neoplasms/mortality ; Fallopian Tube Neoplasms/surgery ; Female ; Humans ; Middle Aged ; Multivariate Analysis ; Neoadjuvant Therapy ; Paclitaxel/administration & dosage ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/surgery ; Progression-Free Survival ; Proportional Hazards Models ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Prognostic value of serum HE4 in patients with advanced ovarian, fallopian tube, and peritoneal carcinoma.
Autorzy :
Mi D; Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and Gynecology, No. 156, Nankai Three Road, Tianjin, China. .
Zhang Y; Department of Clinical Laboratory, Tianjin Central Hospital of Obstetrics and Gynecology, No. 156, Nankai Three Road, Tianjin, China.
Pokaż więcej
Źródło :
Archives of gynecology and obstetrics [Arch Gynecol Obstet] 2020 Mar; Vol. 301 (3), pp. 779-785. Date of Electronic Publication: 2020 Feb 08.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor/*blood
Fallopian Tube Neoplasms/*blood
Ovarian Neoplasms/*blood
Peritoneal Neoplasms/*blood
WAP Four-Disulfide Core Domain Protein 2/*genetics
Adult ; Aged ; Fallopian Tube Neoplasms/mortality ; Fallopian Tube Neoplasms/pathology ; Female ; Humans ; Middle Aged ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Peritoneal Neoplasms/mortality ; Peritoneal Neoplasms/pathology ; Prognosis ; Survival Analysis
Czasopismo naukowe
Tytuł :
Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.
Autorzy :
McCool KW; Department of Obstetrics and Gynecology, University of Michigan Medical School, Ann Arbor, Michigan.
Freeman ZT; Unit for Laboratory Animal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
Zhai Y; Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.
Wu R; Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.
Hu K; Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, Michigan.
Liu CJ; Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.
Tomlins SA; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.
Fearon ER; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.; Department of Human Genetics, University of Michigan Medical School, Ann Arbor, Michigan.; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Magnuson B; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan.
Kuick R; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.; Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, Michigan.
Cho KR; Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan .; Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan.; Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan.
Pokaż więcej
Źródło :
Cancer research [Cancer Res] 2020 Feb 15; Vol. 80 (4), pp. 877-889. Date of Electronic Publication: 2019 Dec 05.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Cystadenocarcinoma, Serous/*genetics
Fallopian Tube Neoplasms/*genetics
Neurofibromin 1/*genetics
Ovarian Neoplasms/*genetics
Tumor Microenvironment/*immunology
Animals ; Carcinoma, Endometrioid/genetics ; Carcinoma, Endometrioid/immunology ; Carcinoma, Endometrioid/pathology ; Cystadenocarcinoma, Serous/immunology ; Cystadenocarcinoma, Serous/pathology ; Disease Models, Animal ; Fallopian Tube Neoplasms/immunology ; Fallopian Tube Neoplasms/pathology ; Fallopian Tubes/pathology ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Mice ; Mice, Transgenic ; Myeloid-Derived Suppressor Cells/immunology ; Ovarian Neoplasms/immunology ; RNA-Seq ; T-Lymphocytes, Regulatory/immunology
Czasopismo naukowe
Tytuł :
The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells.
Autorzy :
Hu Z; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Artibani M; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK; Gene Regulatory Networks in Development and Disease Laboratory, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK.
Alsaadi A; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Wietek N; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK; Department of Gynecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford OX3 7LE, UK.
Morotti M; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK; Department of Gynecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford OX3 7LE, UK.
Shi T; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Zhong Z; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Santana Gonzalez L; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
El-Sahhar S; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
KaramiNejadRanjbar M; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Mallett G; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Feng Y; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK.
Masuda K; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Zheng Y; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Chong K; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK.
Damato S; Department of Histopathology, Oxford University Hospitals, Oxford OX3 9DU, UK.
Dhar S; Department of Histopathology, Oxford University Hospitals, Oxford OX3 9DU, UK.
Campo L; Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK.
Garruto Campanile R; Department of Gynecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford OX3 7LE, UK.
Soleymani Majd H; Department of Gynecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford OX3 7LE, UK.
Rai V; Department of Gynaecology, Oxford University Hospitals NHS Trust, Oxford OX3 9DU, UK.
Maldonado-Perez D; Oxford Radcliffe Biobank, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK; NIHR Oxford Biomedical Research Centre, Second Floor, Unipart House Business Centre, Oxford OX4 2PG, UK.
Jones S; Oxford Radcliffe Biobank, Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK.
Cerundolo V; Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK.
Sauka-Spengler T; Gene Regulatory Networks in Development and Disease Laboratory, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford OX3 9DS, UK.
Yau C; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford OX3 7BN, UK; Centre for Computational Biology, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham B15 2TT, UK; Division of Informatics, Imaging and Data Sciences, Faculty of Biology Medicine and Health, The University of Manchester, Manchester M13 9PT, UK; Alan Turing Institute, London NW1 2DB, UK. Electronic address: .
Ahmed AA; Ovarian Cancer Cell Laboratory, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK; Nuffield Department of Women's & Reproductive Health, University of Oxford, Oxford OX3 9DU, UK; Department of Gynecological Oncology, Churchill Hospital, Oxford University Hospitals, Oxford OX3 7LE, UK. Electronic address: .
Pokaż więcej
Źródło :
Cancer cell [Cancer Cell] 2020 Feb 10; Vol. 37 (2), pp. 226-242.e7.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Epithelial Cells/*pathology
Fallopian Tube Neoplasms/*metabolism
Fallopian Tubes/*pathology
Ovarian Neoplasms/*pathology
Cystadenocarcinoma, Serous/genetics ; Cystadenocarcinoma, Serous/metabolism ; Cystadenocarcinoma, Serous/pathology ; Epithelium/metabolism ; Epithelium/pathology ; Fallopian Tube Neoplasms/genetics ; Fallopian Tube Neoplasms/pathology ; Fallopian Tubes/metabolism ; Female ; Gene Expression Regulation, Neoplastic/genetics ; Genetic Heterogeneity ; Humans ; Ovarian Neoplasms/metabolism
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies